nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2021-01-20. See notice: 10.1039/d1ra90010b.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-A7EC4922·Framework v5.0·Pipeline v0.4·Evaluated 30 May 2026·OECD: 3.1 Basic medicine·Subfield: Molecular Biology·Basis: Full text·Type: Laboratory experiment

Retracted Article: Circular RNA hsa_circ_0000467 modulates SGK1 to facilitate cell migration, metastasis, and EMT while repressing apoptosis in colorectal cancer by sponging miR-383-5p.

Liu et al.Liu, Sun, Sun·2019·RSC advances·10.1039/c9ra07900a ↗

In brief

An incremental circRNA sponge axis characterization in colorectal cancer, competently executed but limited by formulaic design and overclaimed metastasis findings.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

Recent data indicated that circular RNAs (circRNAs) were implicated in tumor progression including colorectal cancer (CRC). However, the mechanism of hsa_circ_0000467 in CRC remains unclear. The levels of hsa_circ_0000467, microRNA-383-5p (miR-383-5p), and serum/glucocorticoid regulated kinase 1 (SGK1) in CRC tissues and cells were measured by quantitative real-time polymerase chain reaction (qRT-PCR). The cell viability and apoptotic rate were detected through cell counting kit-8 (CCK-8) assay and flow cytometry, respectively. The migration and invasion abilities were evaluated via Transwell assay. The protein levels of cleaved caspase 3 (C-caspase 3), B-cell lymphoma 2 (Bcl-2), N-cadherin, E-cadherin, SGK1, and proliferating cell nuclear antigen (PCNA) were detected by western blot assay. The dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay were constructed to verify the interaction between miR-383-5p and hsa_circ_0000467 or SGK1. The mouse model experiment was performed to further validate the effects of hsa_circ_0000467 on CRC progression. Hsa_circ_0000467 and SGK1 were enhanced while miR-383-5p was reduced in CRC tissues and cells. Hsa_circ_0000467 silencing suppressed cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) but induced apoptosis in CRC cells by regulating miR-383-5p. Hsa_circ_0000467 sponged miR-383-5p and SGK1 was a direct target of miR-383-5p. Besides, hsa_circ_0000467 promoted SGK1 expression in CRC cells by sponging miR-383-5p. Furthermore, miR-383-5p restrained cell proliferation, metastasis, and EMT but facilitated apoptosis in CRC cells by modulating SGK1. Also, hsa_circ_0000467 knockdown blocked xenograft tumor growth in vivo. Hsa_circ_0000467 promoted CRC progression by regulating SGK1 expression via miR-383-5p.

Strengths · Limitations

Strengths

#methodological rigour

Thorough mechanistic validation of the sponge axis

The dual-luciferase reporter assays with wild-type and mutant constructs, combined with RIP assays, provide mechanistic evidence for both the hsa_circ_0000467/miR-383-5p and miR-383-5p/SGK1 interactions. Rescue experiments (si-circ + anti-miR; miR + SGK1 overexpression) appropriately establish epistatic relationships.

↳ Results: Figs. 3F, 3G, 4, 5H, 5I, 6

#methodological rigour

Appropriate circRNA validation and in vivo confirmation

RNase R resistance assay validates the circular nature of hsa_circ_0000467, a necessary step. The xenograft model provides a level of in vivo evidence beyond pure cell-line work, demonstrating tumor growth suppression with circRNA knockdown.

↳ Results: Fig. 1C (RNase R); Fig. 7 (xenograft)

#reporting

Clear experimental logic and argument structure

The paper progresses systematically from expression profiling in tissues and cells, through loss-of-function experiments, to interaction validation and rescue experiments, following a coherent investigative narrative.

↳ Results sections 1-7; Figs. 1-7

Limitations

#methodological rigour

Exclusive use of MSI-H cell lines limits generalizability

Both CRC cell lines used (LoVo and HCT116) are microsatellite instable (MSI-H), representing a minority of CRC cases. This restriction to MSI-H lines is not acknowledged or discussed, and findings may not transfer to the majority microsatellite-stable (MSS) CRC population.

↳ Methods: Cell Culture

#reporting

Overclaiming of metastasis from non-metastasis assays

The paper claims effects on 'metastasis' throughout the title, abstract, and results, but the experimental evidence comprises Transwell migration/invasion assays and a xenograft tumor growth model. Neither assay measures metastasis, which is a complex multi-step in vivo process not assessed in this study.

↳ Title; Abstract; Results sections 4 and 6

#methodological rigour

Weak statistical reporting and absent limitations

Only P < 0.05 significance thresholds are reported without exact p-values, test statistics, confidence intervals, or effect sizes. Correlation scatter plots lack reported r values. No limitations section discusses the modest sample size (N=35), cell line selection, or translational gap.

↳ Methods: Statistical Analysis; Figs. 3A, 5A, 5B; Discussion (absent limitations)

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

This paper applies a well-established circRNA ceRNA paradigm to characterize the hsa_circ_0000467/miR-383-5p/SGK1 axis in colorectal cancer. The experimental battery is competent and era-appropriate, with particular strength in the dual-luciferase and rescue experiments that validate the proposed sponge mechanism. However, the exclusive use of two MSI-H cell lines without acknowledgment limits generalizability to the broader CRC population, and the systematic use of 'metastasis' to describe Transwell invasion and xenograft tumor growth results represents an overclaim. Statistical reporting falls short of current standards, with only significance thresholds reported and no exact p-values, effect sizes, or correlation coefficients for key scatter plots. The absence of a limitations section compounds these concerns. These factors collectively place the work as competent but formulaic within its niche, with limited translational potential in its current form.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.9±0.1

Contribution
2.9

The paper applies the well-established circRNA-miRNA-mRNA ceRNA paradigm to a new axis combination (hsa_circ_0000467/miR-383-5p/SGK1) in CRC, extending prior work on this circRNA in gastric cancer. The advance is incremental within a crowded literature, and no specific clinical or therapeutic gap is identified beyond general CRC mechanism elucidation.

Introduction, paragraphs 2-3; Discussion

the mechanism of hsa_circ_0000467 remains unknown in CRC

Methodological Rigour
2.9

The experimental battery is competent and era-appropriate, including RNase R validation, dual-luciferase reporter assays with WT/mutant constructs, RIP assays, rescue experiments, and a xenograft model. However, statistical reporting is weak (only P < 0.05 thresholds, no exact p-values, test statistics, or effect sizes), only two MSI-H cell lines are used without justification, and the xenograft model lacks metastasis-specific endpoints despite metastasis claims.

Methods: Statistical Analysis; Results: Figs. 1-7; Cell Culture section
Reporting
3.0

The paper follows a logical progression from expression profiling through functional characterization to mechanistic validation. However, a nomenclature error (SGK2 for SGK1 in the final Results paragraph), grammatical issues ('To sun up'), and systematic overclaiming of 'metastasis' from Transwell invasion data reduce precision.

Results, final paragraph; Results section 3; Title

The regulatory mechanism of circ_0000467/miR-383-5p/SGK2 in CRC

Positioning
2.7

Relevant prior work on circRNAs, miR-383, and SGK1 in cancer is cited and the findings are connected to existing literature. However, no limitations section is present; the paper does not acknowledge the MSI-H cell line restriction, the modest tissue sample size (N=35), or the gap between xenograft findings and clinical relevance.

Introduction; Discussion; absent Limitations section

Reliability

Concerns4 of 4 checks


Internal CoherenceNoted

The paper contains a nomenclature error (SGK2 instead of SGK1 in the final Results paragraph describing Fig. 8), overclaiming of 'metastasis' from Transwell invasion and xenograft tumor growth data, and correlation scatter plots without reported r or p values. These are notable issues but do not invalidate the core experimental findings.

Research ConductNoted

Ethics approval for animal work is declared. Human tissue consent is stated but the ethics statement inappropriately references NIH animal care guidelines (NIH Publication No. 85-23 Rev. 1985) for human tissue collection. No IRB approval number is provided for the human tissue component. No conflict of interest statement or data availability statement is present.

Flags: 1 declared / 5 total

Reference IntegrityClean

All 28 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2021-01-20. See notice: 10.1039/d1ra90010b.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Colon and rectum cancer
Type of advanceEmpirical
Route to useNot stated
AdvanceExtends
BeneficiariesLarge
CitationsFWCI 0.1
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The mechanism was demonstrated under controlled conditions in CRC cell lines and a mouse xenograft model, with no human clinical or pilot testing.

The discussion and conclusion report only mechanistic findings, stating no real-world use, application, or actor for these results.

Pathway

Oncology researchers and drug developers could pursue hsa_circ_0000467 or the miR-383-5p/SGK1 axis as a colorectal cancer therapeutic target or biomarker.

Barrier

Effects are shown only in cultured CRC cells and mouse xenografts, with no human clinical validation or proven way to deliver circRNA-targeted therapy.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression

    Min-Cheng Yu, Guang-Yu Ding, Peng Ma, et al. · 2021 · Clinical medicine

    Evidence Score
    3.2±0.2
    Reliability
    Caveats
  2. Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496

    Fu, Liu, Zhao, et al. · 2023 · Clinical medicine

    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  3. CircUBAP2 Promotes MMP9-Mediated Oncogenic Effect via Sponging miR-194-3p in Hepatocellular Carcinoma

    Liu, Tian, Chen, et al. · 2021 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    Caveats

How the rubric works →